Edgewise Therapeutics, Inc.
EWTX
Classificação em ações
#4059
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Preço da ação
$37.15
Última sincronização: 2026-10-16
Valor de mercado
$4.00B
Variação (1 dia)
-2.75%
Variação (1 ano)
146.68%
País
US
Negociar Edgewise Therapeutics, Inc. (EWTX)
Categoria
Healthcare
EPS de Edgewise Therapeutics, Inc. (EWTX)
EPS em June 2026 TTM: $-1.85
De acordo com os últimos relatórios financeiros e o preço das ações da Edgewise Therapeutics, Inc., o EPS atual da empresa (TTM) é $-1.85. No final de 2023, a empresa teve um EPS de $-1.57, um aumento em relação a ao EPS de 2022, que foi de $-1.26.
Histórico de EPS da Edgewise Therapeutics, Inc. de 2019 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-1.85 | 27.59% |
| 2024 | $-1.45 | -7.64% |
| 2023 | $-1.57 | 24.60% |
| 2022 | $-1.26 | 46.51% |
| 2021 | $-0.86 | 145.71% |
| 2020 | $-0.35 | 84.21% |
| 2019 | $-0.19 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -1,036.22% |
US
|
|
| $-7.98 | 331.35% |
US
|
|
| $-5.29 | 185.95% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,599.46% |
NL
|
